PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors

PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors

Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline...

Full description

Bibliographic Details
Main Authors: Foteinos-Ioannis Dimitrakopoulos, Achilleas Nikolakopoulos, Anastasia Kottorou, Fotini Kalofonou, Elias Liolis, Theodora Frantzi, Ioannis Pyrousis, Angelos Koutras, Thomas Makatsoris, Haralabos Kalofonos
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
NSCLC
immunotherapy
lung cancer
prognostic
predictive
biomarkers
Online Access:https://www.mdpi.com/2072-6694/12/5/1257

Internet

https://www.mdpi.com/2072-6694/12/5/1257

Similar Items